TNFRSF17 and plasma cell myeloma: In another report, although the fourth dose raised the level of neutralizing antibodies from 80 to 96% at one month after the booster in multiple myeloma patients, anti-BCMA (B cell maturation protein) treatment affected the level of neutralizing antibodies after the third and fourth vaccine dose (8).